期刊文献+

反相高效液相色谱法测定奥沙利铂的含量 被引量:17

RP-HPLC method for determination of Oxaliplatin content
下载PDF
导出
摘要 目的:建立奥沙利铂反相高效液相色谱(RP-HPLC)含量测定方法。方法:采用RP-HPLC测定奥沙利铂的含量,色谱柱:kromasil C18柱(150mm×4.6mm),检测波长250nm。流动相:甲醇-水(5:95),流速:1.0ml/min。结果:本法线性范围为20μg/ml-100μg/ml,r=0.9999。日内和日间精密度RSD分别为0.71%和0.97%(n=5)。平均回收率为99.82%,RSD为0.89%。结论:该测定方法专属性强,操作简便,准确度高,精密度高,可作为奥沙利铂的含量测定方法,以控制其原料及制剂的质量。 Objective: To establish a RP-HPLC method for determination of Oxaliplatin content. Methods: The content of Oxaliplatin was determined by RP-HPLC. kromasil C18 column was used. The detection wavelength was set at 250nm. The mobile phase consisted of methanol-water(5:95) with the flow rate 1.0ml/min. Results: The method was linear within the range of 20-100μg/mL, r=0.9999. The within- day and between-day precisions were 0.71% ( n=5 ) and 0.97% ( n=5 ) respectively. The average recovery of the assay was 99.82% and RSD was 0.89%. Conclusion: The method appeared to be simple and rapid, highly accurate and precise. It can be used for quantitative determination of Oxaliplatin and its preparation.
出处 《抗感染药学》 2005年第1期24-24,26,共2页 Anti-infection Pharmacy
  • 相关文献

参考文献3

二级参考文献26

  • 1Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial[J].Lancet, 2000, 355(9209): 1041-1047.
  • 2Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel[J].Biochem Pharmacol, 1996,5
  • 3Giacchetti S, Perpoint B, Zidani R, et al. Phase Ⅲ multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer[J].J Clin Oncol, 2000, l8(1): 136-147.
  • 4Wasserman E, Cuvier C, Lokeic F, et al. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase Ⅰ studies with pharmacokinetics[J]. J Clin Oncol, 1999,17(6): 1751-1759.
  • 5Scheithauer W, Kornek GV, Raderer M, et al. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer[J]. J Clin Oncol, 1999, 17(3): 902-906.
  • 6Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer[J]. J Clin Oncol, 2004, 22(1): 23-30.
  • 7Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer[J]. Lancet, 1998, 352(9138): 1413-1418.
  • 8Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer[J].Lancet, 1998, 352(9138): 1407-1412.
  • 9Kabbinavar F, Hurwitz H, Fehrenbacher L, et al. Phase Ⅱ, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer[J].J Clin Oncol, 2003, 21(1): 60-65.
  • 10Cuningham D, Humblet Y, Siena S, et al. Cetuximab alone or in combination with irinotecan in patients with epidermal growth-factor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer[C]. Proc Am Soc Clin Oncol, 2003, Abstract :1012.

共引文献50

同被引文献107

引证文献17

二级引证文献64

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部